Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710032, China
NCT Number: NCT02329977
ERCP is the primary choice for removal of common bile duct stone (CBDS) currently. However, 4-24% patients underwent recurrence after successful clearance of CBDS. Stone re-formation due to chronic inflammation of biliary duct is generally considered an important cause of CBDS recurrence, which is associated with duodenal-biliary reflux (DBR) after sphincterotomy. Although it was believed that DBR was the important cause of CBDS recurrence, the direct evidence was still lacking. Here we conducted a case control study to investigate the DBR rate in patients with recurrent CBDS after ERCP.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Xi'an, Shaanxi, 710032, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
Time frame: up to 6 months
The proportion of patients with barium reflux into bile duct during the standard barium meal examination.
Time frame: up to 6 months
MRCP revealed the first angulation from the ampullary orifice along the course of the common bile duct stone.
Time frame: up to 6 months
Maximal CBD diameter was determined by MRCP.
Time frame: up to 6 months
Peripapillary diverticulum was defined endoscopically as the presence of a diverticulum within a 2-cm radius from the papilla and was divided into 2 types in terms of the relation between the papilla and diverticulum: type A, papilla located on the inner rim of the diverticulum or papilla located deep within the diverticulum; and type B, papilla located outside the diverticulum.
Time frame: up to 6 months
Pneumobilia were determined by CT
Air Force Military Medical University, China
Other
Rate of Duodenal-biliary Reflux Increases in Patients With Recurrent Common Bile Duct Stones: Direct Evidence From Barium Meal Examination
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01678391
Biliary Tract Diseases, Calculi
San Francisco, California, United States
View Trial DetailsNCT07002619
Biliary Tract Diseases, Calculi
Stockholm, Sweden
View Trial DetailsNCT01189734
Biliary Tract Diseases, Calculi
Al Mansurah, Dakahlia Governorate, Egypt
View Trial DetailsNCT01190332
Biliary Tract Diseases, Calculi
Al Mansurah, Dakahlia Governorate, Egypt
View Trial Details